Mild Cognitive Impairment
Conditions
Brief summary
The purpose of this study is to evaluate the improving effects of ω-3 fatty acid from fish oil combined with polyphenolic extract from pine bark (PE) on cognitive functions and biological parameters in healthy people aged 55 to 75.
Detailed description
Sixty participants who meet the inclusion criteria will be randomly divided into two groups. Participants in FO group will be provided one capsule of fish oil (350mg EPA + 250mg DHA) per day for 6 months. Moreover, participants in FOPE group will be provided one capsule of fish oil (350mg EPA + 250mg DHA) combined with PE (100mg Oligopin) per day for 6 months. A cognitive function evaluation, blood biological analysis and antioxidative status will be carried out at the baseline, 3 th month and the end of the supplementation period. On the other hand, blood fatty acid composition will be measured at the baseline and the end of the supplementation period. All participants will come to laboratory and receive the supplements every month. At the same time, they will accept the measurement of body weight and blood pressure, also be interviewed with 24 hours dietary recall questionnaire.
Interventions
DIETARY_SUPPLEMENTFOPE (fish oil + pine extract)
During the experiment period the participants will receive a capsule of pine bark extract (Oligopin® 100mg) and a capsule of fish oil (EPA 350mg + DHA 250mg) a day. Blood collecting (biomedical parameters and antioxidative status) and cognitive function evaluation will be examined at the 0, 12, 24th week. Body composition, 24-hour dietary recall and blood pressure measurement will be measured at 0, 4, 8, 12, 16, 20, 24th week.
OTHERFO (fish oil +placebo)
During the experiment period the participants will receive a capsule of placebo (maltodextrin + magnesium stearate) and a capsule of fish oil (EPA 350mg + DHA 250mg) a day. Blood collecting (biomedical parameters and antioxidative status) and cognitive function evaluation will be examined at the 0, 12, 24th week. Body composition, 24-hour dietary recall and blood pressure measurement will be measured at 0, 4, 8, 12, 16, 20, 24th week.
Sponsors
Taipei Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
55 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* I. 55\ 75 years old * II. No severe diseases, such as hyperlipidemia, diabetes, heart diseases, cancer etc. * III. Mini-mental state examination (MMSE) score is more than 26 * IV. Clinical dementia rating scale (CDRS) score is less than 0.5
Exclusion criteria
* liver disease, kidney disease, hypertension, hyperlipidemia, anemia, cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mini-Mental State Examination (MMSE) | Change from Baseline and the 12th and 24th week, the experiment will least for 6 months | The most commonly used cognitive function assessment tool in clinical. |
| Clinical Dementia Rating Scale (CDRS) | Change from Baseline and the 12th and 24th week, the experiment will least for 6 months | CDR is a rating scale for staging patients diagnosed with dementia. no dementia (CDR = 0), questionable dementia (CDR = 0.5), MCI (CDR = 1), moderate cognitive impairment (CDR = 2), and severe cognitive impairment (CDR = 3) |
| Cognitive Ability Screening Instrument (CASI) | Change from Baseline and the 12th and 24th week, the experiment will least for 6 months | CASI is a cognitive test screening for dementia. For monitoring the disease progression and providing profiles of cognitive impairment by examining abilities on attention, concentration, orientation, short-term memory, long-term memory, language abilities, visual construction, list-generating fluency and abstraction. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| An outcome related with hematology- platelet | Change from Baseline and the 12th and 24th week, the experiment will least for 6 months | Platelet in 1000/uL |
| Nutritional status | Change from Baseline and the 12th and 24th week, the experiment will least for 6 months | Serum albumin is in gram per deciliter |
| Liver function -AST | Change from Baseline and the 12th and 24th week, the experiment will least for 6 months | Serum AST is in units per liter. |
| Liver function -ALT | Change from Baseline and the 12th and 24th week, the experiment will least for 6 months | Serum ALT is in units per liter. |
| Kidney function -BUN | Change from Baseline and the 12th and 24th week, the experiment will least for 6 months | Serum BUN is in milligram per deciliter |
| Kidney function -Creatine | Change from Baseline and the 12th and 24th week, the experiment will least for 6 months | Serum creatine is in milligram per deciliter |
| Kidney function -uric acid | Change from Baseline and the 12th and 24th week, the experiment will least for 6 months | Serum uric acid is in milligram per deciliter |
| Lipid profile | Change from Baseline and the 12th and 24th week, the experiment will least for 6 months | Serum HDL-Cho, LDL-Cho, triglyceride and total cholesterol are in milligram per deciliter |
| An outcome related with hematology- white blood cell related measurements | Change from Baseline and the 12th and 24th week, the experiment will least for 6 months | Serum WBC in 1000/uL; neutrophils, lymphocytes, monocytes, eosinophils and basophils are in percentage. |
| An outcome related with hematology- red blood cell related measurements | Change from Baseline and the 12th and 24th week, the experiment will least for 6 months | RBC in 1000000/uL |
| Antioxidative status -TBARS | Change from Baseline at the 12th and 24th week | Thiobarbituric acid-reactive substance |
| Antioxidative status -GSH/GSSG | Change from Baseline and the 12th and 24th week, the experiment will least for 6 months | glutathione/oxidized glutathione ratio |
| Antioxidative status-Oxidized LDL | Change from Baseline and the 12th and 24th week, the experiment will least for 6 months | Oxidized LDL |
| Antioxidative status-SOD | Change from Baseline and the 12th and 24th week, the experiment will least for 6 months | Superoxide dismutase |
| Lipid composition on red blood cell membrane | Change from Baseline and the 12th and 24th week, the experiment will least for 6 months | Lipid composition on the cell membrane of red blood cell. It will be analyzed by GC/MS system and based on the protocol of Wang et al. The composition of C16:0, C18:0, C18:1, C18:2, C18:3, C20:4, C20:5, C22:5, C22:6, saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, total n-3 fatty acids, total n-6 fatty acids and the ratio of n-3 and n-6 will be measured. C16:0, C18:0, C18:1, C18:2, C18:3, C20:4, C20:5, C22:5, C22:6, saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, total n-3 fatty acids, total n-6 fatty acids are in percentage. |
Countries
Taiwan
Contacts
Primary ContactSuh-Ching Yang
Outcome results
None listed